Winclove is an innovative SME based in Amsterdam, the Netherlands. It was founded in 1991 and currently employes 45 people. Winclove develops high quality, stable food supplements.

The company develops, produces, investigates and sells multispecies probiotic products as food supplements for human consumption to most European countries and to multiple other countries in North America, South America and Asia. The average yearly production is 55 million daily doses for end-consumers.

Winclove’s activities in the consortium focus on

  • Developing markers for strain safety
  • Validating molecular markes for strain performance.

Winclove has a strong expertise in leading research projects with multiple partners. Examples of such national projects are CRIB (development of a new and potent probiotic strain for hospital, FND-07013), Panda-II (Translational research to study the effect and mechanism of microbiota in paediatric immune-mediated diseases, FND-06015), and the effect of probiotics on the intestinal flora and immune parameters after treatment with antibiotics (TSGE1041).

Read more about Winclove